PDF
FLIP
Fecha Publicación: 2014-12-19
Cómo citar
Guzmán Terán, C., Villa Dangond, H., & Torres Ayazo, O. (2014). Eritrodermia descamativa agresiva, reacción adversa en paciente tratado con hidroclorotiazida: Reporte de caso. Biosalud, 13(2), 113–117. Recuperado a partir de https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678
Más formatos de cita
Autores/as
Resumen
Se describe un caso clínico de un hombre de 69 años, hipertenso que recibió tratamiento con hidroclorotiaziada 25 mg día y desarrolló una reacción adversa compatible con una eritrodermia descamativa. El paciente experimentó mejoría clínica y resolución total de sus problemas cutáneos cuando finalizó el uso de la hidroclorotiazida.
Palabras clave:
Citas
Beijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24:46-54.
Dormann H, Mulh-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22:161-168.
Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrology 2012; 13:96.
Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007; 63:187-195.
Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol 2012; 29 (4): 412-419.
Product Information. Tekturna HCT(R) oral tablets, aliskiren hydrochlorothiazide oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2012.
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9.
Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring. Center. J Rheumatol 2001; 28:1180-7.
Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013; 8(7):e68938.
Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn B, Dubois EL, et al., eds. Dubois’ Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007; 7.
Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49-51.
Richard R, Tigh J, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T Cell Lymphoma Prospective Analysis and Case Series. Cancer 2013; 119:825-31.
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus British Journal of Dermatology 2011; 164:465-472.
Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed 2000; 16:121-124.
Bartolo L, Valverde J, Rojas P, Vicuña D. Eritrodermia adquirida en un adulto. Dermatol Perú 2010; 20(1):116-120.
Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosisfungoidesa disease of antigen persistence. Br J Dermatol 1974; 91:607-616.
Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767-771.
Schjott J, Bergman J. Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety 2014; 6:89-92.
Dormann H, Mulh-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22:161-168.
Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrology 2012; 13:96.
Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007; 63:187-195.
Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol 2012; 29 (4): 412-419.
Product Information. Tekturna HCT(R) oral tablets, aliskiren hydrochlorothiazide oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2012.
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9.
Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring. Center. J Rheumatol 2001; 28:1180-7.
Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013; 8(7):e68938.
Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn B, Dubois EL, et al., eds. Dubois’ Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007; 7.
Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49-51.
Richard R, Tigh J, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T Cell Lymphoma Prospective Analysis and Case Series. Cancer 2013; 119:825-31.
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus British Journal of Dermatology 2011; 164:465-472.
Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed 2000; 16:121-124.
Bartolo L, Valverde J, Rojas P, Vicuña D. Eritrodermia adquirida en un adulto. Dermatol Perú 2010; 20(1):116-120.
Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosisfungoidesa disease of antigen persistence. Br J Dermatol 1974; 91:607-616.
Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767-771.
Schjott J, Bergman J. Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety 2014; 6:89-92.
Descargas
Los datos de descargas todavía no están disponibles.
